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Summary The oestrogen induced pS2 protein was measured in the cytosol of446 breast cancer samples by an
immunoradiometric assay. The relationships between pS2 and several clinical and biological parameters were
evaluated. pS2 was not correlated to age, pT and nodal status, while it was higher in pre- than in peri- and
post-menopausal women. A statistically significant positive association was found between pS2 and ER, PgR
and cathepsin D. However, the frequency of pS2 negative values in ER+ (25.6%), PgR+ (21.7%) and
cathepsin D-(19.0%) cases suggests that pS2 provides information independent of the above parameters in a
fairly high percentage of patients. The prognostic role of pS2 was evaluated in 267 cases (follow up time
24-102 months). pS2+ showed longer RFS (P = 0.016) and OS (P = 0.004) than pS2-. pS2+ cases were
significantly associated with a better prognosis in N+ but not in N- cases. Multivariate analysis showed that
pS2 is an independent prognostic factor being the second most effective indicator for OS after nodal status and
the third for RFS after nodal status and cathepsin D.
From the present findings, we conclude that pS2 probably provides additional biological information to
steroid receptor status and cathepsin D in patients with primary breast cancer.
The majority of published studies show that oestrogen recep-
tor (ER) status in breast cancer is completely predictive
neither for prognosis nor for responsiveness to endocrine
treatment (for review see Thorpe, 1988). Two hypotheses
have been proposed to explain the lack of response to endo-
crine therapy in patients with ER+ tumours: (1) the tumour
is heterogeneous and expressed both ER+ and ER- cell
clones; (2) ER could be defective; the receptor protein,
although capable of interacting with its specific hormone,
might not activate the sequence of events responsible for the
ultimate hormonal effect. Indeed, histochemical studies
clearly demonstrate that a high percentage, if not all, of
ER+ tumour samples shown heterogeneous ER expression
(Arvan, 1992). However, the simultaneous determination of
ER by both biochemical and histochemical methods could
improve the predictive value of ER status. On the other
hand, defective forms of ER molecules have been recently
demonstrated (Fuqua et al., 1991; Sluyser & Wittliff, 1992).
Regarding this latter aspect, cell products synthesised
under oestrogen control have been thoroughly investigated
(Adams et al., 1983). Their expression would indeed indicate
an effective ER machinery. The determination of pro-
gesterone receptor (PgR), which is synthesised under oest-
rogen control (Horwitz & McGuire, 1978), provided addi-
tional information concerning prognosis and responsiveness
to endocrine therapies. However, despite many published
studies, there is still much controversy regarding the
usefulness of PgR in addition to ER. Indeed, about 20% of
ER+ PgR + cases did not respond to endocrine therapy
(Thorpe, 1988). Further, several authors have shown that
PgR is a better prognostic factor than ER (Clark et al., 1983;
Alexieva-Figush et al., 1988), whereas others have found that
the predictive value of ER overcomes that of PgR (Rayter,
1991; Aaltomaa et al., 1991). Most likely, ER and PgR have
a different prognostic meaning in different subgroups of
patients (Thorpe, 1988).
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Among the oestrogen regulated parameters, the human
pS2 gene, which is specifically transcribed under oestrogen
control (Jacowlew et al., 1984), has been identified in MCF-7
breast cancer cell lines by Masiakowski et al. (1982). The pS2
gene has been cloned and the encoded protein identified as
an 84 amino acid secreted protein whose functions are still
unknown (Masiakowski et al., 1982; Nunez et al., 1987; Rio
& Chambon, 1990).
Using monoclonal antibodies, the pS2 protein was detected
in about 50% of breast cancers where it showed a cytoplas-
matic staining with a tendency to perinuclear condensation
(Henry et al., 1991).
Preliminary studies showed that the pS2 positivity is
mainly restricted to samples expressing ER (Rio et al., 1987;
Foekens et al., 1990; Schwartz, 1991) and is predictive for a
better prognosis (Foekens et al., 1990). Conversely, Henry et
al. using an immunohistochemical method did not find a
significant correlation between pNR-2/pS2 staining and time
to relapse or overall survival (Henry et al., 1991). More
recent data (Predine et al., 1992), showed that pS2 is exp-
ressed also in a fraction of ER negative tumours and that the
prognostic value of pS2 is limited to cases with very low
levels of the protein, which indeed showed a poorer prog-
nosis.
In the present study we evaluated pS2 protein in relation
to steroid receptor status, cathepsin D and the cytosol levels
of the tumour marker tissue polypeptide antigen, that
belongs to the cytokeratin family (Mellerick et al., 1990). The
two latter cytoplasmic proteins are prognostic indicators in
patients with breast cancer (Spyratos et al., 1989, Gion et al.,
1993).
Materials and methods
Four hundred and forty-six patients with primary breast
cancer have been evaluated. Inclusion criteria were as fol-
lows:
(1) stage 1-3 infiltrating breast carcinoma;
(2) no previous or concomitant malignancies of other
organs;
(3) no older than 75 years of age;
(4) no irradiation, chemotherapy or endocrine therapy
prior to surgery.
Patients whose last menstrual cycle occurred less than 2
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years previously were included in the peri-menopausal group;
100 (24.3%) patients were pre-, 33 (8.1%) peri- and 279
(67.7%) post-menopausal; menopausal status was not
available in 34 cases. Staging was performed according to
TNM criteria; 187 (44.1%) patients were pT1, 216 (50.9%)
were pT2 and 21 (5.0%) were pT3; in 22 cases pT was
unknown. Nodal status was pathologically ascertained in all
patients. Two hundred and forty-five (54.9%) were N- and
201 (45.1%) N+.
The primary tumour was treated with radical surgery
(Patey mastectomy) or QUART (quadrantectomy plus
radiotherapy). Patients without axillary involvement (N-)
had no further therapy. Cases with axillary metastases (N+)
were treated with adjuvant chemotherapy (six cycles of
cyclophosphamide/methotrexate/5-fluorouracil, CMF) in pre-
menopausal and tamoxifen 20mg/day for 3 years in post-
menopausal. Study of the prognosis was possible in 267
patients in which a minimum follow-up time of 24 months
(range 24-101 months) was available. Tissue samples were
obtained fresh from the operating room, handled on ice and
stored in liquid nitrogen within 30min.
Cytosol was obtained through pulverisation by a mic-
rodismembrator as previously described (Gion et al., 1986).
ER and PgR were measured using a radioligand binding
assay set up according to the standards suggested by EORTC
(EORTC Breast Cancer Cooperative Group, 1980). The level
of 10 fmol mg-' of cytosolic protein was used throughout to
categorise both ER and PgR as positive or negative.
Cathepsin D and the tissue polypeptide antigen in the
cytosol (cTPA) were measured using commercially available
methods (ELSA Cathepsin D, CIS International, Gif-Sur-
Yvette, France; TPA IRMA, Sangtec Medical, Bromma,
Sweden). The latter was validated for use in cytosol as
previously described (Gion et al., 1986). The value of
31 ngmg-' of cytosolic protein for cathepsin D and 490
U mg-' of cytosolic protein for TPA were used as positive/
negative cutoff points.
pS2 was measured in cytosol samples using a commercially
available immunoradiometric assay (ELSA-pS2T, CIS Inter-
national, Gif-sur-Yvette, France) according to the instructions
of the manufacturer. Briefly, 0.2 ml of '25I-labelled mono-
clonal antibody anti-pS2 and 0.2 ml of standard or diluted
cytosol samples are dispensed into test tubes coated with a
second anti-pS2 monoclonal antibody. After incubation for
1 h at room temperature under agitation, samples are washed
three times with distilled water and bound radioactivity is
counted. Within-assay and between-assay variability was
excellent, the coefficient of variation among 20 determina-
tions of the same cytosol sample being lower than 5%.
The accuracy of the assay was evaluated using the dilution
test (Yalow & Berson, 1968) applied to several cytosol sam-
ples. The recovery ranged from 90 to 101% with a dilution























Cytosol levels (ng mg-' cp)
Figure 1 Evaluation of the best cut off value of cytosol pS2 for
prediction of RFS (thin line) and OS (thick line) (each cut off
value was plotted against its P value). The dotted line represents
the percentage of positive cases.
The protein concentration was determined using the
Coomassie brilliant blue method (Bio-Rad, Richmond, CA,
USA). The cytosolic parameters examined were expressed in
relation to mg of cytosolic protein.
Considering that few clinical data on the most reliable
positive/negative cutoff point for pS2 are so far available, we
categorised pS2 in tumour samples using two criteria.
(1) In some instances we subdivided the distribution of
levels of pS2, cathepsin D, ER and PgR into three groups
(below the 40th percentile, between the 40th and the 60th
percentile and above the 60th percentile value of the distri-
bution found in tumour samples). The Pearson x2 statistic
was thus applied.
(2) Conversely, for the assessment of the relation between
pS2 and prognosis we chose a single +/- cutoff point
selected with the graphic method first described by Tandon et
al. (1990). Several pS2 values are plotted against the P value
of the differences of percentage of relapse and death between
pS2+ and pS2- cases. In the examined patient series, the
most effective pS2 value capable of discriminating between
good and poor prognosis was 4 ng mg-' cytosolic protein for
both relapse-free survival (RFS) and overall survival (OS)
(Figure 1). The same method for the identification of the best
cutoff point has been previously used for the evaluation of
the prognostic value of the other parameters studied in the
present investigation (Gion et al., 1993).
The relapse-free survival (RFS) and the overall survival
(OS) were calculated by the Kaplan-Meier product limit
method. Analysis of RFS and OS were performed using the
logrank univariate (Peto et al., 1977) and the Cox multi-
variate method (Cox, 1972). All computations were carried
out using the BMDP statistical software.
Results
pS2 distribution in tumour samples examined was not Gaus-
sian (Kolmogorov-Smirnov test P<0.001). Using the cutoff
point of a 4 ng mg'I cytosolic protein calculated as
previously described, 177 cases (59.6%) were pS2+ and 120
(40.4%) pS2- in the 297 patients in which the prognosis was
evaluable (all the evaluated prognostic factors were available
in 267 cases). In the entire series the distribution of pS2+
and pS2- cases was not significantly different, the figures
being 248 (55.6%) and 198 (44.4%) respectively.
pS2 levels andage, menopausal status, tumour size, nodal
status, cathepsin D and cTPA
No significant associations were found between pS2 levels
and age, tumour size and the number of positive lymph
nodes.
pS2 was significantly higher in pre- (median 20.2 ng mg-l
cytosolic protein, interquartile 2.9-55.6) than in peri-
(median 5.6 ng mg- cytosolic protein, interquartile 0.7- 19.1)
and in post-menopause (median 4.0 ngmg' cytosolic pro-
tein, interquartile 0.9-25.2, P= 0.0001).
The association between pS2 and cathepsin D, although
statistically significant using both linear correlation and
Spearman Rank correlation (both P< 0.001), was weak as
shown by the regression coefficients (linear regression
r= 0.281, Spearman r= 0.166).
Table I summarises the distribution of pS2 in relation to
cathepsin D status. Patients were subdivided into three
groups according to cathepsin D levels using the same
criteria used for pS2 (below the 40th percentile, between 40th
and 60th percentile and above the 60th percentile value). A
slightly but significantly higher frequency of cases with
elevated pS2 occurred in samples in which cathepsin D was
higher.
No relationships were found between pS2 and cTPA.
pS2 andsteroid receptor status
No significant linear correlation was found between pS2 and
either ER or PgR concentrations (E = 116.0 + 0.285 pS2,
V.VVV * . V
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Table I Distribution of pS2 in relation to cathepsin D concentration
pS2
<4 4-14 > 14
Cathepsin D ngmg-' c.p. ngmg-' c.p. ngmg-' c.p. Total
<31 ngmg-' c.p. 84 38 53 175
31-42 ngmg-' c.p. 39 19 32 90
>42ngmg-' c.p. 71 25 81 177
Total 194 82 166 442
Pearson X2 = 10.12 (P = 0.0385); c.p. = cytosolic protein.
n = 446, r = 0.071, P= 0.134. PgR = 102.6 + 0.36 pS2, n=
446, r = 0.083, p = 0.081).
However, a significant association was found between pS2
and both ER and PgR, as shown in Tables II and III.
The majority of cases with pS2>4ngmg-' of cytosolic
protein (234/248, 94.4%) were found in the tumours which
express measurable ER levels (> 5 fmol mg-' cytosolic pro-
tein), whereas when ER was not expressed pS2 was positive
in 14 samples only (5.6% of the pS2 positive cases) (Pearson
X2= 57.61; P<0.0001).
Concerning PgR, 224/248 (90.3%) pS2+ cases were found
in samples in which PgR is measurable whereas only 24
(9.7%) cases occurred in PgR- tumours (Pearson
x2= 44.70; P<0.0001).
Table III shows the expression of pS2 in relation to ER
and PgR, both categorised using 10 fmol mg-' cytosolic pro-
tein as a positive/negative cutoff point. Concerning the 248
pS2+ cases, 174 (70.2%) were found in ER+PgR+ sam-
ples, 38 (15.3%) in ER+PgR-, 24 (9.7%) in ER-PgR+
and only 12 (4.8%) in ER-PgR-. It is particularly
noteworthy that pS2 was negative in 80/254 ER + PgR+
cases (31.5%), 34/72 (47.2%) ER+PgR- cases and 17/41
(41.5%) ER-PgR+. In these patients, which represent the
29.4% of the evaluated series, pS2 provides information that
is discordant with that of steroid receptors.
pS2 andprognosis - univariate analysis
The potentially prognostic parameters included in the
univariate analysis were: patient's age and menopausal status
at diagnosis, type of treatment of primary tumour (QUART,
Patey mastectomy), type of adjuvant therapy (no therapy,
CMF, tamoxifen), histologic type, axillary status, size of
primary tumour, ER, PgR, pS2, cathepsin D and cytosol
TPA. Nodal status, tumour size and pS2 were significant
prognostic indicators for both RFS and OS; ER and PgR
were related to OS and cathepsin D to RFS only (Table IV).
pS2+ patients showed a longer RFS and OS than pS2-
(Figures 1 and 2). After stratification according to several
variables, pS2+ cases showed a better prognosis than pS2-
only in some subgroups of patients (Table V). RFS and OS
differed significantly between pS2+ and pS2- cases in post-
menopausal as well as in N+, ER-, PgR- patients. The
value of 4 ng mg-' cytosolic protein chosen as the cutoff
point could have been inadequate in premenopausal patients
in which pS2 was higher than in postmenopausal. Therefore,
several other cutoff points were evaluated, failing however to
distinguish between higher and lower risk patients.
Stratifying cases according to cathepsin D, pS2+ cases
showed a better prognosis than pS2-. The difference was
statistically significant in cathepsin D- subgroup for RFS
and in cathepsin D+ for OS.
pS2 andprognosis - multivariate analysis
The association between covariates and survival was
evaluated using the multivariate analysis (Cox, 1972).
Covariates entered in the analysis were: menopausal status,
lymph node status, tumour size, ER, PgR, cathepsin D, pS2
and cTPA. Patients were stratified according to nodal status.
Cathepsin D, pS2, cTPA and tumour size, were independent
prognostic indicators for RFS; pS2, cathepsin D and cTPA
for OS (Table VI).
The most effective prognostic indicators after the nodal
Table II Distribution of pS2 in relation to ER or PgR concentration
pS2
<4 4-14 > 14
ER ngmg-' c.p. ngmg-' c.p. ngmg-' c.p. Total
<Sfmolmg-' c.p. 66 6 8 80
5-20fmolmg-' c.p. 31 17 36 84
>20fmolmg-' c.p. 101 59 122 282
Total 198 82 166 446
Pearson x2= 57.61 (P<0.0001)
PgR
<5 fmol mg-' c.p. 61 10 14 85
5-20fmolmg-' c.p. 59 19 37 115
>20fmolmg-' c.p. 78 53 115 246
Total 198 82 166 446
Pearson %2 = 44.70 (P<0.0001)
Table III Distribution of pS2 in relation to steroid receptor status
pS2
Steroid <4 4-14 > 14
receptor statusa ngmg-' c.p. ngmg-' c.p. ngmg-' c.p. Total
ER-PgR- 67 5 7 79
ER-PgR+ 17 7 17 41
ER+PgR- 34 13 25 72
ER+PgR+ 80 57 117 254
Total 198 82 166 446
Pearson x2 = 70.08 (P<0.0001); apositive/negative cutoff point 10 fmol mg'-I cyto-
solic protein for both ER and PgR; c.p. = cytosolic protein.PS2 IN BREAST CANCER 377
Table IV Prognostic factors evaluated - univariate analysis
Cases RFS OS
Parameter (267) % Censored P (Mantel Cox) % Censored P (Mantel Cox)
N- 150 84.7 90.0
Nodal status <0.0001 0.0005
N+ 117 63.2 73.5
< 2 cm 111 82.9 88.3
Tumor size 0.0278 0.0868
>2 cm 156 69.9 78.8
<10 78 74.4 75.6
ER status 0.494 0.0151
>10 189 75.7 85.7
<10 104 73.1 78.8
PR status 0.541 0.1464
> 10 163 76.7 85.3
<31 103 87.4 89.3
Cath D 0.0003 0.0222
> 31 164 67.6 78.7
<500 137 69.3 75.9
TPA 0.0287 0.0088
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survival curves stratified by axillary nodal
status were cathepsin D for RFS and pS2 for OS. ER and
PgR did not show an independent prognostic role probably
because they are closely related to pS2. Indeed, when ex-
cluding pS2 from the analysis the expression of ER was
significantly related to a longer OS (data not shown).
Discussion
About 25-30% of patients with breast cancer without axil-
lary metastases will suffer from recurrence and die of the
disease (Tubiana & Koscielny, 1991). Therefore, the manage-
ment of patients with breast cancer requires the identification
of reliable prognostic parameters in order to evaluate the risk
of recurrence in N-patients (Ingle, 1991). Moreover, the fre-
quency of N- cases, which is close to 50%, is expected to
further increase as a consequence of early diagnosis and
screening programme (Duffy et al., 1991).
Several potentially prognostic biological parameters have
been evaluated or are under investigation (Foekens et al.,
1991). The use of a panel of prognostic parameters should be
advisable because to date an 'absolute' prognostic factor has
not yet been identified (Ingle, 1991; Foekens et al., 1991).
The choice of the parameters to include in the panel should
take into consideration several items (Ingle, 1991) such as:
the independence of the parameter of other prognostic fac-
tors, the availability of easy and reproducible methods of
determination and the possibility of measuring the parameter
in small amounts of tissue.
The oestrogen induce protein pS2 is indeed measurable
with a reliable and reproducible method in small quantities
of tissue and seems independent of several prognostic
parameters such as age, stage, T and N (Rio et al., 1987;
Foekens et al., 1990; Schwartz et al., 1991; Predine et al.,
1992). Partially conflicting findings are reported by Henry et
al. (1991), who used an immunohistochemical technique and
found a significant association between pNR-2/pS2 positivity
and both low histological grade and smaller tumour size.
The present study confirms that pS2 is an effective prog-
nostic factor in some subgroups of patients with breast
cancer. Our data show a more limited prognostic difference
between pS2+ and pS2- cases than Foekens et al. (1990),
who however used a much higher cutoff point. Conversely,
our data are more in agreement with those of Predine et al.
(1992), although their prognostic cutoff point is much lower
than ours. Probably, differences in assay methods may justify
at least in part the different cutoff points found in the three
different studies. Thus Predine et al. (1992) used an ELISA
method that recorded levels of pS2 lower than those
measured in our series by IRMA. Foekens et al. (1990) used
an IRMA method with loose components. The pS2 standard
was not as highly purified as that of the commerically
available IRMA kit used in the present study (Foekens et al.,
1991).
Although pS2 is biologically related to steroid receptors,
published studies do not elucidate whether or not pS2 and
steroid receptors provide redundant information (Rio et al.,
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Table V Prognostic role of pS2 - univariate analysis
pS2 RFS Os
Strata status Cases % Censored P (Mantel Cox) % Censored P (Mantel Cox)
none + 177 80 88
0.016 0.004
- 120 67 74
pre + 69 80 n.s. 88 n.s.
- 26 73 77
menop.
post + 94 81 0.0109 88 0.0077
- 78 65 73
N- + 91 87 n.s. 91 n.s.
- 59 81 88
N+ + 72 72 0.0095 85 0.0009
- 45 49 55
ER ) 10 + 138 78 n.s. 88 n.s.
fmolmg-' c.p. - 51 69 80
ER<10 + 25 92 0.0149 92 0.0356
fmol mg-' c.p. - 53 66 68
PgR ) 10 + 124 78 n.s. 86 n.s.
fmol mg-' c.p. - 39 72 82
PgR< 10 + 39 87 0.0124 95 0.0039
fmolmg c.p. - 65 65 69
cath-D<31 + 59 95 0.0153 95 n.s.
- 44 77 82
cath-D > 31 + 104 72 n.s. 85 0.0160
- 60 60 68
n.s.: P>0.05; c.p. = cytosolic protein.
Table VI Cox's stepwise proportional hazard model (lymph node
status was used for stratification)
Improvement Global
Covariatea Chi square P value Chi square P value
a Relapse free survival analysis
cathepsin D 9.989 0.002 9.090 0.003
pS2 8.239 0.004 17.623 <0.001
TPA 3.692 0.055 21.217 <0.001
pT 2.880 0.090 24.299 <0.001
b Overall survival analysis
pS2 8.399 0.004 8.753 0.003
cathepsin D 4.446 0.095 13.001 0.002
TPA 4.632 0.031 17.275 0.001
aCovariates used in the multivariate analysis are: menopausal
status, lymph node status, tumour size, ER, PgR, cathepsin D, pS2
and cTPA.
al., 1991; Predine et al., 1992). In the present study the
multivariate analysis suggests that pS2 and ER information
overlap. The two parameters seem therefore alternative prog-
nostic indicators. However, the association between pS2 and
steroid receptors, although evident, is not absolute, which is
in agreement with findings of other authors (Schwartz et al.,
1991; Henry et al., 1991; Predine et al., 1992). Analysing
individual patients, the proportion of pS2- cases in the
ER+ or PgR+ group is elevated. Further follow up data are
necessary to verify if in these cases, pS2 really indicates a
group with poor prognosis.
The pS2+ cases which occur in the ER- and/or PgR-
patients are also of relevance. Their frequency is close to
figures found by Henry et al. (1991) and Predine et al. (1992)
and higher than that found by Foekens et al. (1990). The
pS2+ ER-PgR- phenotype, although occurring in a
limited percentage of cases, may provide clinically useful
information because the expression of pS2 may be indicative
of a functioning ER machinery.
This seems confirmed in the present study by the
favourable prognostic behaviour of pS2+/ER- or PgR-
cases.
Other mechanisms may be implicated in the regulation of
pS2 expression, however. It has been shown that pS2 gene
transcription is oestrogen independent in stomach mucosa,
probably being regulated by EGF or c-Ha-ras and c-jun
proteins (Nunez et al., 1989; Wright et al., 1990).
To our knowledge, no published data are available con-
cerning the association between pS2 and cathepsin D. We
demonstrate here that cathepsin D level correlate weakly
with pS2. This could have been expected since both are
somewhat under oestrogen control (Jacowlew et al., 1984;
Westley, 1987). However, the multivariate analysis clearly
demonstrated that cathepsin D and pS2 provided independent
prognostic information. Moreover, pS2 is an effective prog-
nostic indicator in both cathepsin+ and cathepsin- cases.
In the present study pS2 is also independent of cytosol
TPA, which is related to steroid receptors (Gion et al., 1986)
and provides effective prognostic information in breast
cancer (Gion et al., 1993).
From the present findings we can draw the following
conclusions:
(1) in patients which breast cancer pS2 is a prognostic
parameter independent of tumour size, nodal status, cathep-
sin D and cTPA;
(2) concentrations of pS2 are not closely related to ER or
PgR concentrations in individual patients;
(3) in the present series the prognostic information provided
by pS2 seems to be more effective than that of ER and/or
PgR alone;
(4) although further studies are needed to confirm these
findings in a wider patient series, pS2 does not provide an
alternative to steroid receptors for the assessment of endo-
crine status of the tumour.
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